权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

High-throughput Identification of Membrane Protein MAbs

膜蛋白单克隆抗体的高通量鉴定

基本信息

批准号：
8831071
负责人：
Benjamin Jacob Doranz
金额：
$ 22.48万
依托单位：
INTEGRAL MOLECULAR
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-02-01 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8831071
关键词：
Abbreviations Biomedical Research Cell Surface Proteins Cell membrane Cell surface Cells Complement Development Diagnostic Diagnostics Research Epitopes Exhibits FDA approved Goals Human Human Cell Line Immunization Industry Libraries Membrane Membrane Proteins Methods Molecular Molecular Conformation Monoclonal Antibodies Mutation Nutrient Orphan Performance Phage Display Pharmaceutical Preparations Phase Plasmids Protein Array Proteins Proteome Public Health Qualifying Reagent Reproducibility Services Signal Transduction Source Specificity Staining method Stains Surface System Technology Testing Therapeutic Therapeutic Agents Therapeutic Monoclonal Antibodies Time Tissues United States National Institutes of Health cell type commercial application human disease novel strategies protein expression public health relevance research study screening success therapeutic development trafficking

项目摘要

DESCRIPTION (provided by applicant): Membrane proteins control the flow of information, nutrients, and signals through the cell membrane, and are the targets for more than 40% of FDA-approved drugs. Monoclonal antibodies (MAbs) that target membrane proteins can be exceptionally useful in research, diagnostic, and therapeutic applications, but for most membrane proteins there are no MAbs that recognize the native protein on the cell surface. The need for such MAbs has been recognized by industry and the NIH, but efforts to identify such MAbs are limited by the difficulty in expressing and purifying membrane proteins in exogenous systems and by conventional MAb isolation strategies that typically focus on one target at a time. A novel approach to identify membrane protein MAbs in a high-throughput manner is needed to derive MAbs against the entire human membrane proteome. Here we propose a platform technology that can be used to rapidly isolate MAbs against structurally-intact membrane proteins for therapeutic development, diagnostics, and biomedical research.

描述（由申请人提供）：膜蛋白控制信息、营养物质和信号通过细胞膜的流动，并且是超过 40% FDA 批准的药物的靶标。靶向膜蛋白的单克隆抗体 (MAb) 在研究、诊断和治疗应用中非常有用，但对于大多数膜蛋白来说，没有能够识别细胞表面天然蛋白的 MAb。工业界和 NIH 已经认识到对此类 MAb 的需求，但鉴定此类 MAb 的努力受到外源系统中表达和纯化膜蛋白的困难以及通常一次只关注一个靶标的传统 MAb 分离策略的限制。需要一种以高通量方式鉴定膜蛋白单克隆抗体的新方法，以衍生针对整个人膜蛋白质组的单克隆抗体。在这里，我们提出了一种平台技术，可用于快速分离针对结构完整的膜蛋白的单克隆抗体，用于治疗开发、诊断和生物医学研究。